Soleno Therapeutics to Participate in Upcoming February Investor Conferences

Rhea-AI Summary

Soleno Therapeutics (NASDAQ: SLNO), a clinical-stage biopharmaceutical company focused on rare disease therapeutics, has announced its participation in two major investor conferences this February. The company will present at the Guggenheim SMID Cap Biotech Conference on February 6, 2025, at 2:00 PM ET in a fireside chat format, and at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 2:40 PM ET as a corporate presentation.

Both presentations will be available via webcast, with replay options accessible through the Investors section of Soleno's website at www.soleno.life.

News Market Reaction – SLNO

+0.97%

+0.97% Session move

In the trading session that priced this news, SLNO gained 0.97%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February:

Guggenheim SMID Cap Biotech Conference
Presentation Date: Thursday, February 6, 2025 at 2:00 PM ET
Presentation Format: Fireside Chat
Webcast: https://wsw.com/webcast/guggen2/slno/2028708

Oppenheimer 35^th Annual Healthcare Life Sciences Conference
Presentation Date: Tuesday, February 11, 2025 at 2:40 PM ET
Presentation Format: Corporate Presentation
Webcast: https://wsw.com/webcast/oppenheimer39/slno/2814816

A replay of both events will be available in the Investors section on the Company’s website at www.soleno.life.

About Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

FAQ

When is Soleno Therapeutics (SLNO) presenting at the Guggenheim SMID Cap Biotech Conference?

Soleno Therapeutics will present at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025, at 2:00 PM ET.

What type of presentation will SLNO deliver at the Oppenheimer Healthcare Conference?

SLNO will deliver a corporate presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.

How can investors access the webcasts of SLNO's February 2025 conference presentations?

Investors can access the webcasts through specific links provided for each conference, and replays will be available in the Investors section of Soleno's website at www.soleno.life.

What is the timing of SLNO's presentation at the Oppenheimer Conference in February 2025?

Soleno Therapeutics will present at the Oppenheimer Conference on Tuesday, February 11, 2025, at 2:40 PM ET.

Which investor conferences is SLNO participating in during February 2025?

SLNO is participating in the Guggenheim SMID Cap Biotech Conference and the Oppenheimer 35th Annual Healthcare Life Sciences Conference in February 2025.